Boston Scientific's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Boston Scientific's ROA in the third quarter of 2026?
Boston Scientific Corporation achieved a return on average assets (ROA) of 7.79 % in its third quarter of 2026, this is above BSX's average return on assets of 0.22%.
Boston Scientific Corporations assets during the 12 months ending in the third quarter of 2026 are valued at $44 billion

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 118 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 750, from total ROA ranking in the second quarter of 2026 at 1050.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	7.43 %	9.25 %	10.49 %	22.2 %	24.65 %
Y / Y Net Income Change	-23.18 %	13.84 %	99.26 %	19.01 %	61.32 %
Net Income (TTM) in million	3,494	3,669	3,559	2,892	2,785
Return On Assets (TTM)	7.79 %	8.33 %	8.26 %	6.88 %	6.96 %
BSX's Total Ranking	# 750	# 1050	# 908	# 987	# 1157
Total Assets (TTM) in million	45,878	45,403	44,351	43,673	42,707
Seq. Total Assets Change	1.05 %	2.37 %	1.55 %	2.26 %	2.76 %
Seq. Net Income Change	-35.91 %	-32.41 %	99.85 %	-11.26 %	-5.03 %

BSX's 5 Years Annual ROA >> Back to BSX Management Effectiveness >> Compare BSX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 35
Sector	# 119
Overall	# 786

Return On Assets Statistics
High	Average	Low
18.17 %	0.22 %	-27.61 %
(Dec 31 2019)		(June 30, 2006)

Financial Statements
Boston Scientific's Assets	$ 45,878 million	BSX's Balance sheet
Boston Scientific's Income	$ 580 million	Quarterly BSX's Income Statement
BSX's Income by Division		See BSX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	22.2 %	14.2 %	9.7 %	1.57 %	5.72 %
Total Assets in million	43,673	35,740	31,295	28,527	28,087
Y / Y Net Income Change	56.66 %	15.95 %	128.08 %	-32.95 %	-
Net Income in million	2,892	1,846	1,592	698	1,041
Annual Return On Assets	6.62 %	5.17 %	5.09 %	2.45 %	3.71 %

BSX's 5 Years Annual ROA >> Back to BSX Management Effectiveness >> Compare BSX ROA to its Competitors

Comment on BSX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.62 % compared to prior year, due to annual net income growth of 56.66 % to $2,892.00 million, while value of Boston Scientific's overall assets grew just by 22.2 % to $43,673.00 million, compared to $43,673.00 a year before.

More Return On Assets Ratios
BSX's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BSX's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BSX's Competitors
Subscribers only: Roa for Boston Scientific's Suppliers
Subscribers only: Return On Assets for BSX's Customers

You may also want to know
BSX's Roi	BSX's Inventory Turnover Ratio	BSX's Growth Rates	BSX's Dividend Comparisons
	BSX's Profitability Ratios	BSX's Asset Turnover Ratio	BSX's Dividend Growth
BSX's Roe	BSX's Valuation Ratios	BSX's Financial Strength Ratios	BSX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %
Inspire Medical Systems inc	10.89 %
Transmedics Group Inc	10.67 %
Bristol myers Squibb Company	10.47 %
Lemaitre Vascular Inc	10.28 %
Beone Medicines Ltd	10.23 %

Date modified: 2026-11-03T09:56:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.